Journal Articles
Disclaimer: The papers below are intended for private viewing by the page owner or those who otherwise have legitimate access to them. No part of it may in any form or by any electronic, mechanical, photocopying, recording, or any other means be reproduced, stored in a retrieval system or be broadcast or transmitted without the prior permission of the respective publishers. If your organization has a valid subscription of the journals, click on the DOI link for the legitimate copy of the papers.
View By Year Published
2018-2019
Raffa RB, Taylor R Jr, Pergolizzi JV Jr.
Treating opioid-induced constipation in patients taking other medications: Avoiding CYP450 drug interactions J Clin Pharm Ther 2019;44(3):361-371
Pergolizzi JV Jr., Rosenblatt M, Mariano DJ, LeQuang JA
Clinical considerations about opioid withdrawal symptoms Pain Manag 2019; 9(2):111-113
Pergolizzi JV, LeQuang JA, Passik S, Coluzzi F
Using opioid therapy for pain in clinically challenging situations: questions for clinicians Minerva Anesthesiol 2019; 85(8):899-908
Kitzen JM, McConaha JL, Bookser, ML, Pergolizzi JV Jr, Taylor R Jr, Raffa RB
E-cigarettes for smoking cessation: do they deliver? J Clin Pharm Ther 2019;44(4):650-655
Pergolizzi JV Jr, Rosenblatt M, LeQuang JA.
Three years down the road: the aftermath of the CDC guideline for prescribing opioids for chronic pain Adv Ther 2019;36(6):1235-1240
Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Lara A, Ortiz AH, Iban MAR
Pain Control in Latin America: The Optimized Role of Buprenorphine in the Treatment of Cancer and Noncancer Pain Pain. Pain Ther 8, 187–201 (2019)
Pergolizzi JV, Varrassi G, Paladini A, LeQuang J
Stopping of decreasing opioid therapy in patients on chronic opioid therapy Pain Ther. 2019 Dec;8(2):163-176
DOI:10.1007/s40122-019-00135-6
Varrassi G, Alon E, Bagnasco M, Lanata L, Mayoral-Royals V, Paladini A, Pergolizzi JV, Perrot S, Scarpignato C, Tolle T
Towards an effective and safe treatment of inflammatory pain: a Delphi-guided expert consensus Adv Ther 36, 2618–2637 (2019)
DOI:10.1007/s12325-019-01053-x
Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Bisney J
Tapentadol extended release in the treatment of severe chronic low back pain and osteoarthritis pain Pain Ther 2018;7(1):37-57
Pergolizzi JV Jr., Taylor R, Jr., LeQuang JA, Bisney J. Raffa RB, Pergolizzi F, Colucci D, Batastini L
Driving under the influence of opioids: what prescribers should know J Opioid Manag 2018;14(6):415-427
Pergolizzi, J.V., Annabi, H., Gharibo, C., LeQuang, JA
The Role of Lofexidine in Management of Opioid Withdrawal Pain Ther 2019;8(1)67-78
Raffa RB, Pergolizzi JV Jr, Taylor R Jr, Parker G, Rodenbeck R
Persistence of healthcare-associated (nosocomial) infections due to inadequate hand hygiene: Part 3 – application of human factors engineering to an ozone hand sanitizer Pharmacol Pharm 2018;9:324-330
Raffa RB, Pergolizzi JV Jr, Taylor R Jr, Choudhuri S, Rodenbeck R
Persistence of healthcare-associated (nosocomial) infections due to inadequate hand hygiene: Part 2 – human factors Pharmacol Pharm 2018;9:310-323
Raffa RB, Pergolizzi JV Jr, Taylor R Jr, Choudhuri S, Rodenbeck R
Persistence of healthcare-associated (nosocomial) infections due to inadequate hand hygiene: Part 1 – biological and treatment factors Pharmacol Pharm 2018;9:293-309
Pergolizzi JV Jr, LeQuang JA, Taylor R Jr, Raffa RB
The Place of Community Rescue Naloxone in a Public Health Crisis of Opioid Overdose Pharmacol Pharm 2019, 10, 61-81
Nalamachu S, Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Pergolizzi JV 3rd, Raffa RB
Hormone replacement therapy for restoring the HPG axis in pain patients treated with long-term opioid analgesics Pharmacol Pharm 2018;9:473-480
Pergolizzi JV Jr, Ossipov MH, Taylor R Jr, Raffa RB
‘New-look’ opioids: biased ligands Pharmacol Pharm 2018;9:242-249
Pergolizzi JV Jr, Taylor R Jr, Raffa RB
Crisaborole and apremilast: pde4 inhibitors with similar mechanism of action, different indications for management of inflammatory skin conditions Pharmacol Pharm 2018;9:357-381
Raffa RB, Pergolizzi JV Jr, Taylor R Jr., James RP, Pirner M
Differences in the receptor binding profile of lofexidine compared to clonidine Pharmacology & Pharmacy, 2019, 10, 1-10
Ossipov MH, Pergolizzi JV Jr, Taylor R Jr, Raffa RB
Targets to watch – nerve growth factor (NGF) as a target for the treatment of neuropathic pain Drugs Future 2018;43:655-664
Raffa RB, Pergolizzi JV Jr, Taylor R Jr.
The fist approved ‘deuterated’ drug: a short review of the concept Pharmacol Pharm 2018;9:440-446
Kitzen JM, Pergolizzi JV Jr, Taylor R Jr, Raffa RB
The role of medical literature, clinical trials and experimental research in drug product-injury litigation: a primer with two examples Pharmacol Pharm 2018;9:208-227
Pergolizzi JV Jr, LeQuang JA, Bisney J
Cannabinoid Hyperemesis. Medical Cannabin and Cannabinoids Med Cannabis Cannabinoids 2018;1:73–95
Pergolizzi J, Kowalski M, He E
Effectiveness of once-daily extended-release hydrocodone in individuals previously receiving immediate-release oxycodone for chronic pain Pain Med 2018;19(5):967-977
Raffa RB, Pergolizzi JV Jr, LeQuang JA, Taylor R Jr., Colucci S, Annabi MH
The fentanyl family: a distinguished medical history tainted by abuse J Clin Ther. 2018;43(1):154-158
Meissner W, Huygen F, Neugebauer EAM, Osterbrink J, Benhamou D, Betteridge N, Coluzzi F, De Andres J, Fawcett W, Fletcher D, Kalso E, Kehlet H, Morlion B, Montes Pérez A, Pergolizzi J, Schäfer M
Management of acute pain in the postoperative setting: the importance of quality indicators Curr Med Res Opin 2018; 34(1):187-196
Raffa RB, Pergolizzi JV Jr, Taylor R Jr
The rapid-onset antidepressant effect of ketamine: More surprises? J Clin Pharm Ther 2018;43(2):308-311
Pergolizzi JV Jr, LeQuang JA, Taylor R, Raffa RB
Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances and street heroin Postgrad Med 2018. 130(1):1-8
Raffa RB, Pawasauskas J, Pergolizzi JV Jr, Lu L, Chen Y, Wu S, Jarrett B, Fain R, Hill L, Devarakonda K
Pharmacokinetics of oral and intravenous paracetamol (acetaminophen) when co-administered with intravenous morphine in healthy adult subjects Clin Drug Investig. 2018. 38(3):259-268
Pergolizzi JV Jr, Raffa RB, Taylor R Jr, Vacalis S
Abuse-deterrent opioids: an update on current approaches and considerations Curr Med Res Opin 2018;34(4):711-723
Pergolizzi JV J, LeQuang JA, Taylor R Jr, Raffa RB, Colucci D
The role of cannabinoids in pain control: the good, the bad, and the ugly Minerva Anestesiol 2018 84(8):955-969
Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Raffa RB
Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release products J Pain Res. 2018;11:301-311
Morlion B, Coluzzi F, Aldington D, Kocot-Kepska M, Pergolizzi J, Mangas AC, Ahlbeck K, Kalso E
Pain chronification: what should a non-pain specialist know? Curr Med Res Opin 2018; 34(7):1169-1178
Raffa RB, Pergolizzi JV, Taylor R, Ossipov MH
Nature’s first atypical opioids: kratom and mitragynines J Clin Pharm Ther 2018;43(3):437-441
Pergolizzi JR JV, Taylor R Jr, LeQuang JA, Raffa RB
The role and mechanism of action of menthol in topical analgesic products J Clin Pharm Ther 2018; 43(3):313-319
Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Raffa RB, Bisney J
Tapentadol extended release in the treatment of severe chronic low back pain and osteoarthritis pain Pain Ther 2018; 7(1):37-57
Pergolizzi JV Jr, Coluzzi F, Taylor R Jr
Transdermal buprenorphine for moderate chronic noncancer pain syndromes Expert Rev Neurother 2018; 23:1-11
Raffa RB, Pergolizzi JV Jr, Taylor R Jr., Ossipov MH
Indirect-acting strategy of opioid action instead of direct receptor activation: dual-acting enkephalinase inhibitors (DENKIs) J Clin Pharm Ther. 2018 Aug;43(4):443-449.
Eke-Okoro UJ, Raffa RB, Pergolizzi JV Jr, Breve F, Taylor R Jr.
Curcumin in turmeric: basic and clinical evidence for a potential role in analgesia J Clin Pharm Ther 2018. 43(4):460-464
Pergolizzi JV Jr, Taylor R JR, LeQuang JA, Raffa RB.
What’s holding back abuse-deterrent opioid formulations? Considering 12 US stakeholders Exp Opin Drug Deliv 2018; 15(6):567-576
Raffa RB, Pergolizzi JV Jr, Taylor R Jr, Ossipov MH
Discovery of folded DNA structures in human cells: potential drug targets J Clin Pharm Ther 2019; 44(1):125-128
Pergolizzi JV Jr, LeQuang JA, Taylor R Jr, Ossipov MH, Colucci D, Raffa RB
Designing safer analgesics: a focus on µ opioid receptor pathways Exp Opin Drug Discov 2018; 13(10)965-972
Pergolizzi JV , Rosenblatt M, Mariano DJ, Bisney J
Tapering opioid therapy: clinical strategies Pain Manag 2018;8(6):409-413
Raffa RB, Pergolizzi JV Jr, Taylor R Jr, Kitzen JM
Sunscreen bans: coral reefs and skin cancer J Clin Pharm Ther. 2018; 44(1):134-139